Physician profile
Marc E Phillpotts
NPI 1518300151
$3,286.44
in general payments reported to CMS, 2019-2025
19 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $68.39 · 2021: $480 · 2022: $1,125 · 2023: $947 · 2024: $141 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $773.21 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $689.70 | 2020-2024 | |
| Ucb, INC. | $332.27 | 2019-2023 | Cimzia |
| Glaxosmithkline, LLC. | $238.80 | 2019-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $221.01 | 2019-2023 | |
| Lilly USA, LLC | $202.97 | 2019-2023 | Taltz, Olumiant |
| Pfizer INC. | $162.61 | 2021-2023 | |
| Janssen Biotech, INC. | $145.07 | 2020-2023 | Stelara, Remicade, Simponi Aria |
| Horizon Therapeutics Plc | $118.76 | 2019-2022 | |
| Genzyme Corporation | $118.75 | 2025 | |
| Aurinia Pharma U.S., INC. | $111.99 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.35 | 2022-2023 | Ofev |
| Depuy Synthes Sales INC. | $23.10 | 2023 | Monovisc, Orthovisc |
| E.R. Squibb & Sons, L.L.C. | $22.91 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $18.64 | 2025 | Iovera |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $18.44 | 2022 | |
| Radius Health, INC. | $15.86 | 2019 | |
| Merck Sharp & Dohme LLC | $14.04 | 2019 | |
| Hikma Pharmaceuticals USA | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Phillpotts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.